Trial of tocilizumab for bleeding stroke to prevent later strokes
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if a drug called tocilizumab (TYENNE) can reduce the risk of delayed strokes after a bleeding stroke from a ruptured aneurysm. It is for adults who had a specific type of brain bleed and need a drain to remove fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had a bleeding stroke from a burst aneurysm within the last 24 hours, confirmed by a scan.
- You have a drain placed in your brain or spine (or plan to have one put in).
- If you could become pregnant, a pregnancy test must be negative, and you agree to use non-hormonal birth control or not have sex during the study and for 2 months after the last dose.
- If you are a man with a partner who could become pregnant, you agree to use a condom or not have sex during the study and for 2 months after the last dose, and not donate sperm.
- You are able to attend follow-up visits and give consent (or have someone who can).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a blood-thinning medicine called tirofiban to see if it helps reduce delayed brain damage after a type of stroke from a bleeding brain aneurysm. It is for people who have already had their aneurysm fixed with coiling, and the medicine is given soon after.
This trial tests if a medicine called cilostazol can reduce the risk of a delayed shortage of blood in the brain after having a bleeding aneurysm treated. It aims to improve recovery by preventing a common complication called delayed cerebral ischemia.
This trial tests whether adding a drug called cilostazol to standard care (nimodipine) helps people recover better after a type of stroke caused by a bleeding brain aneurysm. It may help prevent complications like narrowing of blood vessels in the brain.
This trial tests whether the drug ticagrelor, which helps prevent blood clots, can reduce the risk of a stroke occurring days after a mild form of bleeding in the brain. It is given as an add-on to the standard treatment for the bleeding aneurysm.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
This trial tests whether a drug that lowers inflammation can reduce the risk of another stroke in people with narrowing of a brain artery. The treatment is given after a mild stroke or mini-stroke.
Hear when a new Aneurysmal Subarachnoid Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.